Regeneron Pharmaceuticals Inc (REGN.O) CEO CFO Call Series: Top Quotes from Regeneron Call

Research evidence excerpt

Regeneron Pharmaceuticals Inc (REGN.O) CEO CFO Call Series: Top Quotes from Regeneron Call

Flash |

23 Jun 2026 08:19:43 ET │ 11 pages

Regeneron Pharmaceuticals Inc (REGN.O)

CEO CFO Call Series: Top Quotes from Regeneron Call

CITI’S TAKE

We wrapped up our 2026 CEO/CFO call series with Regeneron CFO Chris

Neutral Fenimore, covering capital allocation, BD/M&A, EYLEA-HD, Dupixent

Price (22 Jun 26 16:00) US$612.50 lifecycle management, and pipeline priorities (watch replay key takeaways

here). Management reiterated a familiar framework: prioritize internal Target price US$700.00

R&D, use external innovation selectively, and maintain flexibility on Expected share price return 14.3%

shareholder returns through buybacks and a modest dividend. Product Expected dividend yield 0.1%

commentary was balanced, with confidence in EYLEA-HD momentum Expected total return 14.4%

despite broader retina pressure and constructive updates on Dupixent Market Cap US$64,214M

COPD/CSU uptake, persistence, and lifecycle optionality. Dupixent and

Libtayo remain important supports, but EYLEA franchise pressure, the

need for clearer pipeline conversion, and limited near-term narrative-

changing catalysts keep us on the sidelines. Please see below for top Geoff Meacham, Ph.D.AC

quotes from the discussion. Maintain Neutral, TP $700. +1-404-443-4701

geoffrey.meacham@citi.com

On capital allocation and BD Nishant Gandhi, Ph.D.

+1-212-816-2513

“First and foremost, it’s on our internal R&D innovation engine. What comes behind nishant.gandhi@citi.com

that is effectively looking at external opportunities. We’re open to looking at things

that have nearer-term potential in terms of bringing in revenue. It’s not like we’re just Mary Kate Davis

limiting ourselves to looking at earlier-stage opportunities.